Coveted FDA designations for FORMA Therapeutics

USA-based FORMA Therapeutics today announced the US Food and Drug Administration has granted Fast Track designation and Rare Pediatric Disease designation for its lead clinical asset, FT-4202, in development as a disease-modifying treatment for sickle cell disease (SCD).

FT-4202 is a selective pyruvate kinase-R (PKR) activator that exhibits the potential to beneficially impact both anemia and vaso-occlusive crises for people living with SCD.

FORMA is a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers.